Vimarsana
Biggest News Aggregation in the World

Dial Transplant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dial Transplant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dial Transplant Today - Breaking & Trending Today

Hansa Biopharma AB: Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting - Vimarsana News

Hansa Biopharma AB: Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting

Published: May 21, 2024

LUND, Sweden, May 21, 2024 /PRNewswire/ --. Hansa Biopharma, "Hansa" (NASDAQ: HNSA) (STOCKHOLM: HNSA), today announced data featuring imlifidase will be presented at the American Transplant

Source: finanznachrichten.de
Related Topics:
United KingdomUnited StatesEvan BallantyneHansa BiopharmaStephanie KenneyEuropean Medicines AgencyAmerican Transplant CongressEuropean UnionEuropean Medicines Agency Ema PriorityDrug AdministrationVp Global Corporate AffairsAmerican Society Of TransplantationAmerican Society Of Transplant SurgeonsAmerican SocietyTransplant SurgeonsBiologic License ApplicationGuillain Barre SyndromeExhibit HallBreaking AbstractsClinical Rapid Fire OralHighly Sensitized Kidney Transplant RecipientsPositive Crossmatch AgainstDeceased DonorKidney Transplantations PerformedClinical Outcomes
Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study - Vimarsana News

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data from 17-HMedIdeS-14 study

Published: October 17, 2023

/PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced results...

Source: prnewswire.com
Related Topics:
United StatesUppsala LanLos AngelesStanley JordanHansa BiopharmaStephanie KenneyTomas LorantPrnewswire Hansa BiopharmaKlaus SindahlSinai Medical CenterUppsala University HospitalHmedides Clinical Trial ProgramEuropean UnionEuropean Medicines AgencyAmerican Kidney FundVp Global Corporate AffairsNasdaq StockholmAmerican JournalAssociate ProfessorTransplant SurgeryTransplant ImmunologyCedars Sinai Medical CenterHuman Leukocyte AntigensPriority MedicinesIdes Clinical Trial
Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data - Vimarsana News

Imlifidase demonstrated 90% patient survival and 82% graft survival at five years in extended pooled analysis with data

Published: October 17, 2023

LUND, Sweden, Oct. 17, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in...

Source: notimerica.com
Related Topics:
Uppsala LanUnited StatesHansa Biopharmahansa BiopharmaTomas LorantLos AngelesHansa BiopharmaPrnewswire Hansa BiopharmaStanley JordanKlaus SindahlStephanie KenneyHmedides Clinical Trial ProgramUppsala University HospitalSinai Medical CenterAmerican Kidney FundEuropean UnionEuropean Medicines AgencyNasdaq StockholmAmerican JournalAssociate ProfessorTransplant SurgeryTransplant ImmunologyCedars Sinai Medical CenterHuman Leukocyte AntigensInvestor RelationsmCorporate Affairsm
Idefirix (imlifidase) receives provisional approval in Australia as desensitization treatment in highly sensitized patients prior to kidney transplantation - Vimarsana News

Idefirix (imlifidase) receives provisional approval in Australia as desensitization treatment in highly sensitized patients prior to kidney transplantation

Published: July 11, 2023

/PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that the...

Source: prnewswire.com
Related Topics:
South AustraliaUnited KingdomNew ZealandPrnewswire Hansa BiopharmaHansa BiopharmaKlaus SindahlStephanie KenneyUniversity Of Sydney Clinical Professor Kate WyburnTransplantation NetworkPanel Reactive AntibodyVp Global Corporate AffairsEuropean Medicines Agency Ema PriorityZealand Paired Kidney ExchangeAustralian Therapeutic Goods AdministrationEuropean Medicines AgencyNasdaq StockholmNew Zealand Paired Kidney ExchangeSydney Clinical Professor Kate WyburnAustralian RegisterHuman Leukocyte AntigensEnd Stage Renal DiseaseEnglj MedNew Zealand DialysisTransplant RegistryAnnual Report
Hansa Biopharma AB: Hansa Biopharma announces positive reimbursement decision for Idefirix (imlifidase) in Belgium as desensitization treatment for highly sensitized patients in kidney transplantation - Vimarsana News

Hansa Biopharma AB: Hansa Biopharma announces positive reimbursement decision for Idefirix (imlifidase) in Belgium as desensitization treatment for highly sensitized patients in kidney transplantation

Published: June 1, 2023

LUND, Sweden, June 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that it has attained

Source: finanznachrichten.de
Related Topics:
Region FlamandeStephanie KenneyHansa BiopharmaPrnewswire Hansa BiopharmaDirk KuypersKlaus SindahlDepartment Of NephrologyUniversity Hospitals LeuvenEuropean UnionEuropean Medicines Agency Ema PriorityRenal Transplantation ProgramVp Global Corporate AffairsEuropean Medicines AgencyNasdaq StockholmHuman Leukocyte AntigensProduct CharacteristicsEnd Stage Renal DiseaseDial TransplantEnglj Med